Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

Persistence of Tofacitinib in the Treatment of Rheumatoid Arthritis in Open‐Label, Long‐Term Extension Studies up to 9.5 Years

ABSTRACT Objective Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). This post hoc analysis evaluated tofacitinib persistence in patients with RA in long‐term extension (LTE) studies up to 9.5 years. Methods Data were pooled from two LTE studies: ORAL Sequ...

Full description

Bibliographic Details
Main Authors: Janet E. Pope, Edward Keystone, Shahin Jamal, Lisy Wang, Lara Fallon, John Woolcott, Irina Lazariciu, Douglass Chapman, Boulos Haraoui
Format: Article
Language:English
Published: Wiley 2019-04-01
Series:ACR Open Rheumatology
Subjects:
clinical trial
DMARDs
rheumatoid arthritis
risk factors
Online Access:https://doi.org/10.1002/acr2.1010

Internet

https://doi.org/10.1002/acr2.1010

Similar Items